Nestlé Divests Palforzia Business

Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.

This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

"We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world," said Greg Behar, CEO of Nestlé Health Science. "At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers."

A transition period will ensure business continuity and provide patients uninterrupted access to the treatment.